FATE   $1.1  1.85% Market Closed After Close 1.13 2.73%

Fate Therapeutics, Inc.
Total Cash 304.88M
totalCashPerShare 2.677
EBITDA -163.44M
Total Debt 100.56M
quickRatio 8.842
currentRatio 9.18
Total Revenue 12.32M
debtToEquity 25.332
Revenue/Share 0.119
ROA -0.20497999
ROE -0.42103
grossProfits
freeCashflow -66.67M
operatingCashflow -140.57M
earningsGrowth
revenueGrowth 6.258
grossMargins 0.0
ebitdaMargins 0.0
operatingMargins -6.65727
profitMargins 0.0
enterpriseValue 100.88M
forwardPE -1.5952382
floatShares 98.77M
sharesOutstanding 113.88M
sharesShort 16.06M
sharesShortPriorMonth 15.04M
dateShortInterest
sharesPercentSharesOut 0.14%
heldPercentInsiders 0.02%
heldPercentInstitutions 1.05%
Short Ratio help_outline 14.27%
shortPercentOfFloat 0.16%
impliedSharesOutstanding
bookValue 3.487
Price To Book help_outline 0.77
earningsQuarterlyGrowth
netIncomeToCommon -175.72M
trailingEps -1.70%
forwardEps -1.68%
enterpriseToEbitda -0.62
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.43 3Q 2024
institutionsCount 239
lastUpdated Nov. 6, 2024, 5:23 p.m.